A5089808394- Bone health and treatments
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Management of metastatic bone disease
- Chemotherapy-related skin toxicity
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Medical Imaging and Pathology Studies
- Estrogen and related hormone effects
- Nausea and vomiting management
- Neutropenia and Cancer Infections
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Medical Imaging Techniques and Applications
- Pathogenesis and Treatment of Hiccups
- Prostate Cancer Treatment and Research
- Anesthesia and Pain Management
University of Ottawa
2015-2025
Ottawa Hospital
2015-2024
Ottawa Hospital Research Institute
2015-2024
Ottawa Regional Cancer Foundation
2013-2023
McMaster University
2011-2022
BC Cancer Agency
2009-2021
McGill University
2018
University of Calgary
2011-2018
Juravinski Cancer Centre
2011-2017
Health Sciences Centre
2005-2017
Decisions about systemic treatment of women with metastatic breast cancer are often based on estrogen receptor (ER), progesterone (PgR), and Her2 status the primary tumor. This study prospectively investigated concordance in between tumor distant metastases assessed impact any discordance patient management.
BackgroundDespite the availability of effective antiemetics and evidence-based guidelines, up to 40% cancer patients receiving chemotherapy fail achieve complete nausea vomiting control. In addition type chemotherapy, several patient-related risk factors for chemotherapy-induced (CINV) have been identified. To incorporate these into optimal selection prophylactic antiemetics, a repeated measures cycle-based model predict ≥grade 2 CINV (≥2 episodes or decrease in oral intake due nausea) from...
Purpose To evaluate the safety and efficacy of oral everolimus, a mammalian target rapamycin (mTOR) inhibitor, in two different schedules minimally pretreated patients with metastatic breast cancer to explore for possible biologic correlates response. Patients Methods who received no or one prior chemotherapy regimen were entered onto this multicenter, noncomparative, randomized phase II study everolimus 10 mg daily versus 70 weekly; multinomial end points response progression evaluated at 8...
To evaluate the safety and initial efficacy of magnetic resonance (MR) imaging-guided focused ultrasound for palliation pain caused by bone metastases in patients whom standard available treatments had been ineffective or not feasible.Informed consent was obtained 11 (seven women, four men; average age, 58.6 years) with related to non-weight-bearing who were subsequently treated MR this research ethics board-approved study. Efficacy evaluated changes visual analog scale (VAS) scores,...
Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel patients metastatic triple-negative breast cancer (mTNBC). Methods Eligible who had received ≤1 prior cytotoxic regimen for mTNBC were treated olaparib 200 mg bid continuously plus weekly 90 mg/m 2 three weeks per four-week cycle. Dose modifications large proportion due to neutropenia resulted...
Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society Clinical Oncology (ASCO) guideline on role bone-modifying agents (BMAs) metastatic breast cancer. This focused update addressed new data intervals between dosing and BMAs control bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The reviewed three phase III noninferiority trials intervals, one...
There is a paucity of literature about the benefits bone-targeted agents for breast cancer patients with bone metastases treated in non-trial setting. We explored incidence, consequences, and treatment at single centre.Electronic records metastatic were reviewed pertinent information was extracted.Of 264 patients, 195 (73%) developed metastases. Of these 176 eligible analysis. Median age diagnosis 56.9 years (IQR 48-67) initial presentation included asymptomatic radiological findings (58%),...
This study evaluated whether additional palliative benefits could be derived from the second-line use of more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy pamidronate clodronate.This prospective impact on pain, quality life, and markers turnover (for example, urinary N-telopeptide [NTX]). Patients received monthly (4 mg) for 3 months. Study evaluations were made...
Complementary and alternative medicine (CAM) use is common among cancer patients. This paper reviews the of CAM in a series patients with locally advanced breast (LABC).Women LABC attending specialist clinic at single Canadian centre were identified approached. Participants completed self-administered survey regarding usage, beliefs associated views their risks developing recurrent dying cancer. Responses scored compared between users non-users.Thirty-six approached, 32 questionnaire...
We previously identified claudin-2 as a functional mediator of breast cancer liver metastasis. now confirm that levels are elevated in metastases, but not skin compared to their matched primary tumors patients with cancer. Moreover, is specifically expressed liver-metastatic cells populations derived from bone or lung metastases. The increased tropism exhibited by claudin-2-expressing requires claudin-2-mediated interactions between and hepatocytes. Furthermore, the reduction expression...
Most women with advanced breast cancer will develop bone metastases, which are associated the development of skeletal-related events (sres) such as pathologic fractures and spinal cord compression. This article reviews evolving definition incidence sres, pathophysiology key evidence for safety efficacy currently available systemic treatment options preventing delaying sres in setting metastases.The bisphosphonates structural analogues endogenous pyrophosphate; three them (clodronate,...
Our objective was to evaluate preferences associated with grade I/II and III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that are willing make between treatment the route schedule of administration.In this cross-sectional study, for completed a one-time Web survey. Conjoint analysis used elicit 17 available chemotherapies regimens. In analysis, risk each effect increased by 5%, holding all others constant, respective impact on...
Despite advances in antiemetic therapy, chemotherapy-induced nausea and vomiting (CINV) remains the most feared expected side effect of chemotherapy. Optimization therapy is important because CINV can lead to reduced quality life, increased use health care resources, compromised treatment adherence. The evidence illustrates how recommendations have evolved raises ongoing issues controversies management CINV.
Abstract Background Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three early-stage cancer. Methods Patients with stage I–III were randomly assigned to 3 years intravenous zoledronic acid, oral clodronate, or ibandronate....